Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2025 Feb 26

PMID 40008213

Authors

Huayan Gu

Teng Zhu

JiaLing Ding

Zhi Yang

Shuangyi Qi

Guilong Guo

Affiliations

Soon will be listed here.

Abstract

Purpose: This study efforts to explore the association of adverse events (AEs) with efficacy in HER2-positive breast cancer patients treated with TDM1.

Methods And Materials: This retrospective study included women diagnosed with HER2+ BC treated with TDM1 from January 2012 to December 2023. Event-free survival (EFS) was the endpoint. Tumour response was assessed by disease control rate (DCR) and objective response rate (ORR). The chi-squared test, analysis of variance (ANOVA), Cox proportional hazards regression and Kaplan-Meier survival analysis was employed to evaluate the association of AEs with tumour efficacy.

Results: A total of 48 women with a median age of 52 years (median follow-up 8.4 months) were included in the study. Among them, 33 patients (68.8%) experienced adverse events, including platelet depletion and liver function abnormalities, 3 patients (6.3%) discontinued TDM1 due to severe platelet depletion. The overall objective response rate (ORR) was 25.0% and the disease control rate (DCR) was 43.8%. Using the Chi-squared test, we found a statistically significant difference in ORR and DCR between patients who developed a platelet reduction and those who did not. DCR was significantly higher in patients with liver dysfunction than in those without. ANOVA showed that exposure to hepatic dysfunction and platelet reduction, lines of therapy, and treatment course were associated with EFS. In the Kaplan-Meier survival analysis, both liver dysfunction and platelet reduction were correlated with significantly longer EFS (p=0.033 and p=0.038, respectively).

Conclusion: This retrospective study demonstrated that AEs were associated with tumour efficacy in patients with HER2+ BC treated with TDM1.

References

Kim S, Wildiers H, Krop I, Smitt M, Yu R, Lysbet de Haas S . Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer. 2016; 139(10):2336-42. DOI: 10.1002/ijc.30276. View

Junttila T, Li G, Parsons K, Phillips G, Sliwkowski M . Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2010; 128(2):347-56. DOI: 10.1007/s10549-010-1090-x. View

Fu Z, Li S, Han S, Shi C, Zhang Y . Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7(1):93. PMC: 8941077. DOI: 10.1038/s41392-022-00947-7. View

Robichaux J, Elamin Y, Vijayan R, Nilsson M, Hu L, He J . Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 2019; 36(4):444-457.e7. PMC: 6944069. DOI: 10.1016/j.ccell.2019.09.001. View

Dumontet C, Reichert J, Senter P, Lambert J, Beck A . Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023; 22(8):641-661. DOI: 10.1038/s41573-023-00709-2. View

Endo Y, Takeda K, Mohan N, Shen Y, Jiang J, Rotstein D . Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes. Oncotarget. 2019; 9(98):37200-37215. PMC: 6324681. DOI: 10.18632/oncotarget.26461. View

Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer M . Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021; 39(13):1448-1457. DOI: 10.1200/JCO.20.01204. View

von Minckwitz G, Huang C, Mano M, Loibl S, Mamounas E, Untch M . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018; 380(7):617-628. DOI: 10.1056/NEJMoa1814017. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

10.

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

11.

Perez E, Lysbet de Haas S, Eiermann W, Barrios C, Toi M, Im Y . Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019; 19(1):517. PMC: 6543580. DOI: 10.1186/s12885-019-5687-0. View

12.

Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K . HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer. 2018; 25(5):605-613. PMC: 6132843. DOI: 10.1007/s12282-018-0861-9. View

13.

Tarantino P, Ricciuti B, Pradhan S, Tolaney S . Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023; 20(8):558-576. DOI: 10.1038/s41571-023-00783-w. View

14.

Amiri-Kordestani L, Blumenthal G, Xu Q, Zhang L, Tang S, Ha L . FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014; 20(17):4436-41. DOI: 10.1158/1078-0432.CCR-14-0012. View

15.

Bianchini G, Kiermaier A, Bianchi G, Im Y, Pienkowski T, Liu M . Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res. 2017; 19(1):16. PMC: 5299741. DOI: 10.1186/s13058-017-0806-9. View

16.

Schneeweiss A, Chia S, Hegg R, Tausch C, Deb R, Ratnayake J . Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res. 2014; 16(4):R73. PMC: 4226982. DOI: 10.1186/bcr3690. View

17.

Uppal H, Doudement E, Mahapatra K, Darbonne W, Bumbaca D, Shen B . Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2014; 21(1):123-33. DOI: 10.1158/1078-0432.CCR-14-2093. View

18.

Rassy E, Rached L, Pistilli B . Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. Breast. 2022; 66:217-226. PMC: 9636477. DOI: 10.1016/j.breast.2022.10.016. View

19.

Li G, Guo J, Shen B, Bumbaca Yadav D, Sliwkowski M, Crocker L . Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells. Mol Cancer Ther. 2018; 17(7):1441-1453. DOI: 10.1158/1535-7163.MCT-17-0296. View

20.

Mahalingaiah P, Ciurlionis R, Durbin K, Yeager R, Philip B, Bawa B . Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019; 200:110-125. DOI: 10.1016/j.pharmthera.2019.04.008. View